Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Prior Authorization for GLP-1 Weight Loss Drugs: How to Get Approved for Wegovy, Zepbound, Ozempic, and Mounjaro

By
Published Updated Last reviewed
17 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Labeled for weight management / Wegovy injection and tablets, Saxenda, Zepbound, Foundayo [1][3][4][2]
  • Wegovy weight-management population / Adults with obesity, or overweight plus at least one weight-related condition; children 12 and older [1]
  • Foundayo population / Adults with obesity, or overweight plus at least one weight-related condition [2]
  • Contraindications both labels state / Personal or family history of medullary thyroid carcinoma or MEN 2; prior serious hypersensitivity [1][2]
  • Medicaid unrestricted GLP-1 availability, March 2024 / 60% of fee-for-service plans, 48% of managed care plans [7]

Which GLP-1 products carry a weight-management indication?

Wegovy (semaglutide injection and tablets), Saxenda, Zepbound (tirzepatide) and Foundayo (orforglipron) are FDA approved for weight management [1][3][4][2]. The others are labeled for type 2 diabetes: Ozempic and Rybelsus [5][9]; Victoza and Xultophy [10][11]; Trulicity and Byetta [12][13]; Soliqua [14]. Mounjaro is labeled for type 2 diabetes, while Zepbound has the weight-management indication [4][6].

Wegovy's label also covers cardiovascular risk reduction in adults with established cardiovascular disease plus obesity or overweight [1]. Foundayo's covers weight reduction and maintenance, with no diabetes indication [2].

What the labels say about who qualifies

Wegovy describes the weight-management population as adults with obesity, or adults with overweight plus at least one weight-related comorbid condition, and children aged 12 and older with obesity [1]. Foundayo uses the same adult wording [2].

STEP 1 enrolled 1,961 adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition; semaglutide 2.4 mg produced a mean weight change of -14.9% versus -2.4% on placebo at 68 weeks [15]. SURMOUNT-1 enrolled 2,539 adults on the same criteria, and tirzepatide 15 mg produced -20.9% versus -3.1% at 72 weeks [16].

Both labels contraindicate use with a personal or family history of medullary thyroid carcinoma or MEN 2, and with a prior serious hypersensitivity reaction [1][2].

Why Ozempic and Mounjaro requests are a different question

Ozempic and Mounjaro carry type 2 diabetes indications, while Wegovy and Zepbound carry weight-management indications [5][4][6]. Weight data from diabetes trials describe an effect, not an indication: in STEP 2, mean weight change at 68 weeks was -9.6% on semaglutide 2.4 mg versus -3.4% on placebo among 1,210 adults with type 2 diabetes and a BMI of at least 27 [17].

What published data show about restrictions

Prior authorization is a requirement that the plan approve a drug before it pays for it. In March 2024, 30 of 50 state Medicaid fee-for-service programs (60%) listed at least one GLP-1 receptor agonist without prior authorization or step therapy, as did 131 of 273 managed care plans (48%); 40% of enrollees in those plans had restricted GLP-1 availability, and tirzepatide was almost entirely restricted [7]. That study measured availability for type 2 diabetes, not obesity coverage.

Frequently asked questions

Which GLP-1 drugs are FDA approved for weight management?
Wegovy injection and tablets, Saxenda, Zepbound, and Foundayo [1][3][4][2].
Can Ozempic be approved for weight loss?
Ozempic carries a type 2 diabetes indication, so a request built on weight loss does not match its labeled use [5]. Wegovy carries the semaglutide weight-management indication [1].
What population does the Wegovy label describe?
Adults with obesity, or adults with overweight plus at least one weight-related comorbid condition, and children 12 and older with obesity [1].
How many Medicaid plans list a GLP-1 drug without prior authorization?
In March 2024, 30 of 50 state Medicaid fee-for-service programs (60%) and 131 of 273 managed care plans (48%) listed at least one GLP-1 receptor agonist without prior authorization or step therapy; the study measured availability for type 2 diabetes [7].

References

  1. U.S. National Library of Medicine, DailyMed. Wegovy injection and tablets prescribing information. Wegovy injection and tablets label
  2. U.S. National Library of Medicine, DailyMed. Foundayo (orforglipron) tablets prescribing information. Foundayo (orforglipron) tablets label
  3. U.S. National Library of Medicine, DailyMed. Saxenda injection (liraglutide) prescribing information. Saxenda injection (liraglutide) label
  4. U.S. National Library of Medicine, DailyMed. Zepbound injection (tirzepatide) prescribing information. Zepbound injection (tirzepatide) label
  5. U.S. National Library of Medicine, DailyMed. Ozempic injection prescribing information. Ozempic injection label
  6. U.S. National Library of Medicine, DailyMed. Mounjaro injection (tirzepatide) prescribing information. Mounjaro injection (tirzepatide) label
  7. Makam AN, Bailey L, Anderson N, Bellitti K, Skinner S, Nguyen OK. Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program. Ann Intern Med. 2025;178(6):808-818. Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program
  8. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA
  9. U.S. National Library of Medicine, DailyMed. Rybelsus and Ozempic tablets (oral semaglutide) prescribing information. Rybelsus and Ozempic tablets (oral semaglutide) label
  10. U.S. National Library of Medicine, DailyMed. Victoza injection (liraglutide) prescribing information. Victoza injection (liraglutide) label
  11. U.S. National Library of Medicine, DailyMed. Xultophy 100/3.6 (insulin degludec and liraglutide) prescribing information. Xultophy 100/3.6 (insulin degludec and liraglutide) label
  12. U.S. National Library of Medicine, DailyMed. Trulicity injection (dulaglutide) prescribing information. Trulicity injection (dulaglutide) label
  13. U.S. National Library of Medicine, DailyMed. Byetta injection (exenatide) prescribing information. Byetta injection (exenatide) label
  14. U.S. National Library of Medicine, DailyMed. Soliqua 100/33 (insulin glargine and lixisenatide) prescribing information. Soliqua 100/33 (insulin glargine and lixisenatide) label
  15. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Once-Weekly Semaglutide in Adults with Overweight or Obesity
  16. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Tirzepatide Once Weekly for the Treatment of Obesity
  17. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Evidence overview for Prior Authorization for GLP-1 Weight Loss Drugs: How to Get Approved for Wegovy, Zepbound, Ozempic, and Mounjaro